ICICI Securities: Sudarshan Chemical Industries’ Capex Delayed, But Medium Term Outlook Intact
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Sudarshan Chemical Industries Ltd.’s Q1 FY21 Ebitda dip of 18% YoY to Rs 530 million was higher than expected due to forex gains. Though the company sees capex execution delayed by six months, it remains confident of completion of new project in specialty products by H2 FY22.
Sudarshan Chemical continues to work towards becoming world’s third-largest pigment company (currently the third-largest player has revenues of $500 million) and has adopted three key strategies to reach its goal: 1) improve distribution by better go-to-market plans, 2) enhance product portfolio with specialty pigments, and 3) attain cost leadership.
We see downside risk to our revenue estimate for FY21, but higher gross margin offsets risk at the Ebitda level.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.